IP Library Granted Patent US 11,951,165
Granted Patent B2
US 11,951,165 · App. 16/459,303 · Granted Apr 9, 2024

Conjugated vaccine carrier proteins

Inventors: Jeffery C. Fairman (Mountain View, CA); Jon H. Heinrichs (Doylestown, PA); Wei Chan (San Francisco, CA)
Assignee: Vaxcyte, Inc.
A61K39/385A61K39/092A61P31/04C07K14/001C07K14/285C07K14/33C07K14/34A61K38/00A61K2039/6037A61K2039/627A61K2039/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,951,165
App. No.
16/459,303
Granted
Apr 9, 2024
Kind
B2
Abstract

Methods for the production of immunogenic compositions containing a non-natural amino acid are disclosed. The non-natural amino acid can be a site for attachment of antigens, such as bacterial capsular polysaccharides, to make immunogenic conjugates. Bio-orthogonal attachment chemistry incorporated into the non-natural amino acids allows for more efficient and potent antigen presentation to the immune system, simplified purification, and more well-defined structure of these semi-synthetic immunogens.

Claims (6)

1. A carrier protein for use in a crosslinked protein-antigen conjugate vaccine comprising at least 98% sequence identity to SEQ ID NO:9, wherein:

a 2-amino-3-(4-(azidomethyl)phenyl)propanoic acid (pAMF) non-natural amino acid (nnAA) is present at residues 34, 213, 245, 265, 386, and 527 numbered according to SEQ ID NO:9.

2. The carrier protein according to claim 1 , that does not contain an Arg-Arg dipeptide.

3. The carrier protein according to claim 1 , wherein the carrier protein comprises the sequence of SEQ ID NO:14.

4. A carrier protein for use in a crosslinked protein-antigen conjugate vaccine comprising at least 98% sequence identity to SEQ ID NO:14, wherein:

a 2-amino-3-(4-(azidomethyl)phenyl)propanoic acid (pAMF) non-natural amino acid (nnAA) is present at residues 34, 213, 245, 265, 386, and 527 numbered according to SEQ ID NO:14.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE FIRST INVENTOR PREVIOUSLY RECORDED AT REEL: 049891 FRAME: 0222. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 16, 2020
From: FAIRMAN, JEFFERY C.; HEINRICHS, JON H.; CHAN, WEI; MARCQ, OLIVIER JEAN GÉRARD; BEHRENS, CHRISTOPHER R.
To: SUTROVAX, INC.
Reel/Frame 052948/0378 →
CHANGE OF NAME Recorded May 19, 2020
From: SUTROVAX, INC.
To: VAXCYTE, INC.
Reel/Frame 052698/0221 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2019
From: FREEMAN, JEFFERY C.; HEINRICHS, JON H.; CHAN, WEI; MARCQ, OLIVIER JEAN GÉRARD; BEHRENS, CHRISTOPHER R.
To: SUTROVAX, INC.
Reel/Frame 049891/0222 →
Continuity (8)
Continuation In Part 15859251 · Dec 29, 2017
Provisional Application 62693978 · Jul 4, 2018
Provisional Application 62693981 · Jul 4, 2018
Provisional Application 62591160 · Nov 27, 2017
Provisional Application 62568201 · Oct 4, 2017
Provisional Application 62530803 · Jul 10, 2017
Provisional Application 62441115 · Dec 30, 2016
Related Publication 20200054739A1 · Feb 20, 2020
Cited By (1)
US 12,295,998